Loading the procedure…
Loading the procedure…
Medicare volume, surgeons, state markets and device makers
EBUS, navigational and robotic bronchoscopy, endobronchial valves, VATS lobectomy. Main billing specialties: pulmonary disease and thoracic surgery.
Medicare fee-for-service bronchoscopy & lung nodule cases in the 50 states summed: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 6% on average (216 state-years, 2020–2024): a close guide.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| California | 119 | 8,499+11%/yr | +11%/yr | 2.60.8× | 2% | 16,800 in 2030+12%/yr |
| Florida | 120 | 7,940+6.4%/yr | +6.4%/yr | 3.61.1× | 0% | 13,100 in 2030+8.7%/yr |
| Texas | 98 | 6,069+1.9%/yr | +1.9%/yr | 2.90.9× | 0% | 9,990 in 2030+8.7%/yr |
| Illinois | 82 | 5,581+11%/yr | +11%/yr | 4.11.3× | 0% | 10,800 in 2030+12%/yr |
| Pennsylvania | 75 | 5,343+1.2%/yr | +1.2%/yr | 4.01.3× | 0% | 7,380 in 2030+5.5%/yr |
| New York | 82 | 4,973+1.9%/yr | +1.9%/yr | 2.80.9× | 0% | 7,320 in 2030+6.6%/yr |
| Tennessee | 58 | 3,989+4.5%/yr | +4.5%/yr | 5.71.8× | 2% | 5,930 in 2030+6.8%/yr |
| Ohio | 65 | 3,959+2.2%/yr | +2.2%/yr | 3.61.1× | 0% | 6,330 in 2030+8.1%/yr |
| North Carolina | 56 | 3,414+0.2%/yr | +0.2%/yr | 3.51.1× | 0% | 4,080 in 2030+3%/yr |
| Arizona | 38 | 3,079+16%/yr | +16%/yr | 4.21.3× | 0% | 5,590 in 2030+10%/yr |
| Massachusetts | 48 | 3,057+5.5%/yr | +5.5%/yr | 3.31.0× | 0% | 4,980 in 2030+8.5%/yr |
| Georgia | 43 | 2,875+5.7%/yr | +5.7%/yr | 3.41.1× | 0% | 5,590 in 2030+12%/yr |
| Indiana | 44 | 2,775+5.4%/yr | +5.4%/yr | 4.01.3× | 0% | 4,650 in 2030+9%/yr |
| Michigan | 41 | 2,711−0.1%/yr | −0.1%/yr | 3.31.0× | 0% | 4,390 in 2030+8.4%/yr |
| Virginia | 42 | 2,548+1.9%/yr | +1.9%/yr | 2.50.8× | 0% | 4,620 in 2030+10%/yr |
| Maryland | 33 | 2,509+4.4%/yr | +4.4%/yr | 2.90.9× | 1% | 3,560 in 2030+6%/yr |
| Missouri | 36 | 2,414−2.3%/yr | −2.3%/yr | 3.91.2× | 2% | 2,900 in 2030+3.1%/yr |
| Kentucky | 40 | 2,343+2.3%/yr | +2.3%/yr | 5.21.6× | 0% | 4,370 in 2030+11%/yr |
| Wisconsin | 40 | 2,262+6.8%/yr | +6.8%/yr | 4.11.3× | 1% | 4,120 in 2030+11%/yr |
| New Jersey | 36 | 2,104+9.9%/yr | +9.9%/yr | 2.00.6× | 0% | 4,020 in 2030+11%/yr |
| South Carolina | 29 | 1,874+3.7%/yr | +3.7%/yr | 2.80.9× | 0% | 3,150 in 2030+9%/yr |
| Washington | 31 | 1,779+2.1%/yr | +2.1%/yr | 2.30.7× | 0% | 2,570 in 2030+6.3%/yr |
| Minnesota | 28 | 1,774+6.4%/yr | +6.4%/yr | 4.01.3× | 0% | 3,640 in 2030+13%/yr |
| Colorado | 18 | 1,328+5.9%/yr | +5.9%/yr | 2.80.9× | 0% | 2,020 in 2030+7.2%/yr |
| Kansas | 20 | 1,248+4.7%/yr | +4.7%/yr | 3.11.0× | 0% | 2,190 in 2030+9.8%/yr |
| Mississippi | 20 | 1,240+1.2%/yr | +1.2%/yr | 3.31.1× | 0% | 1,510 in 2030+3.4%/yr |
| Louisiana | 18 | 1,193+5.7%/yr | +5.7%/yr | 3.00.9× | 0% | 2,510 in 2030+13%/yr |
| Iowa | 25 | 1,181+6.7%/yr | +6.7%/yr | 2.70.8× | 0% | 2,360 in 2030+12%/yr |
| Connecticut | 12 | 1,083+3.5%/yr | +3.5%/yr | 3.31.0× | 0% | 2,100 in 2030+12%/yr |
| Arkansas | 16 | 1,036−1.8%/yr | −1.8%/yr | 2.80.9× | 0% | 1,540 in 2030+6.9%/yr |
| Alabama | 19 | 1,031+1.9%/yr | +1.9%/yr | 2.40.8× | 0% | 1,640 in 2030+8%/yr |
| Oklahoma | 14 | 974+2.6%/yr | +2.6%/yr | 2.00.6× | 0% | 2,260 in 2030+15%/yr |
| Nebraska | 19 | 940+6.3%/yr | +6.3%/yr | 3.61.2× | 0% | 1,420 in 2030+7.1%/yr |
| Delaware | 12 | 798+6.5%/yr | +6.5%/yr | 4.71.5× | 0% | 1,560 in 2030+12%/yr |
| Oregon | 10 | 796+5.6%/yr | +5.6%/yr | 1.90.6× | 0% | 1,500 in 2030+11%/yr |
| District of Columbia | 7 | 762+4.4%/yr | +4.4%/yr | 12.23.9× | 0% | 1,250 in 2030+8.6%/yr |
| Nevada | 11 | 545+13%/yr | +13%/yr | 1.90.6× | 0% | 870 in 2030+8.2%/yr |
| West Virginia | 4 | 478−5.3%/yr | −5.3%/yr | 2.30.7× | 0% | 670 in 2030+5.8%/yr |
| Utah | 6 | 444+15%/yr | +15%/yr | 2.10.6× | 0% | 960 in 2030+14%/yr |
| New Hampshire | 8 | 422+0.3%/yr | +0.3%/yr | 1.90.6× | 0% | 790 in 2030+11%/yr |
| North Dakota | 6 | 329+11%/yr | +11%/yr | 3.31.1× | 0% | 750 in 2030+15%/yr |
| South Dakota | 8 | 310+7.1%/yr | +7.1%/yr | 2.40.8× | 0% | 620 in 2030+12%/yr |
| Idaho | 5 | 286+3%/yr | +3%/yr | 1.40.4× | 0% | 650 in 2030+15%/yr |
| Montana | 5 | 277+1.2%/yr | +1.2%/yr | 1.50.5× | 0% | 310 in 2030+1.7%/yr |
| Hawaii | 6 | 241+24%/yr | +24%/yr | 1.90.6× | 0% | 590 in 2030+16%/yr |
| Maine | 3 | 224−7.6%/yr | −7.6%/yr | 1.40.5× | 0% | 320 in 2030+6.4%/yr |
| New Mexico | 4 | 210+8.1%/yr | +8.1%/yr | 0.90.3× | 0% | 570 in 2030+18%/yr |
| Vermont | 4 | 192+6.8%/yr | +6.8%/yr | 1.70.5× | 0% | 560 in 2030+20%/yr |
| Alaska | 2 | 179+25%/yr | +25%/yr | 1.50.5× | 0% | 660 in 2030+24%/yr |
| Rhode Island | 4 | 147+4.9%/yr | +4.9%/yr | 1.60.5× | 0% | 310 in 2030+13%/yr |
Professional codes (what the surgeon bills): CPT 31652, 31653, 31628, 31647, 32663.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed, summed over the states listed: states MedaRep covers where the procedure tops 100 Medicare cases a year. All Medicare adds Medicare Advantage patients at each state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. How the numbers are made · Data sources
In the last 10 years FDA made 112 decisions (510(k) clearances, De Novo grants, PMA approvals and supplements) under this category’s product codes, held by 41 companies. The most active:
Product codes: EOQ (bronchoscope (flexible or rigid)). A company whose devices for this procedure are filed under other codes is not counted, and a PMA supplement counts as a decision of its own. Applicants are rolled up to their parent company.
The competitive landscape: each company scored on innovation pace, recall and report signals, commercial momentum and financial capacity.
The 10 busiest do 33% of the cases CMS names in California; 54 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| Procedure | Surgeons | Medicare FFS | Growth since 2019 | Forecast |
|---|---|---|---|---|
| Colonoscopy & upper endoscopy | 17,732 | 3,622,736−2.9%/yr | −2.9%/yr | 3,877,600 in 2030+1.1%/yr |
| ERCP & endoscopic ultrasound | 1,734 | 112,761−1.2%/yr | −1.2%/yr | 137,600 in 2030+3.4%/yr |
Every procedure · Markets by state · Device companies · Compare two states
In 2025, 34 companies reported engagement with surgeons in the covered states worth $8.4M in consulting, speaking, meals and travel tied to these products, about $5,331 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 11 clearances and approvals in the category, 4 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the state rankings. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.